Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

ConferenceBHV-1530Positive

AI Analysis

Summary

Biohaven's Phase 1 data for BHV-1530, a novel FGFR3-directed antibody-drug conjugate, has been selected for oral presentation at the 38th EORTC-NCI-AACR Symposium 2026.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 findings from BHV1530-101 study selected for oral presentation

Importance:5/10

Sentiment:

0.60

oncologyADCFGFR3conference presentationearly-phase

Related Companies

$ISCO $MOLN $DFPH

Read the original article

Published by PR Newswire Biotech on September 28, 2026 11:30 AM

Read Original